Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing

BOSTON and EDISON, N.J., July 15 /PRNewswire/ -- A sub-analysis of a Phase IIb multinational study(1) with edoxaban(2) - an investigational oral Factor Xa inhibitor - provides insights into why patients with non-valvular atrial fibrillation (AF) receiving edoxaban once daily (QD) experie...

CRESTOR(R) Reduced CV Risk in Patients Achieving Low LDL and hsCRP Targets in New JUPITER Analysis

ORLANDO, Fla., March 29 /PRNewswire-FirstCall/ -- Results from a new sub- analysis of the JUPITER study show that patients with low to normal cholesterol levels and elevated high sensitivity C-reactive protein (hsCRP) who attained a dual treatment target of LDL-C <70mg/dL and hsCRP <2mg/...

CRESTOR(R) Reduced Risk of Blood Clots in the Veins

ORLANDO, Fla., March 29 /PRNewswire-FirstCall/ -- A new analysis from the JUPITER study shows that CRESTOR(R) (rosuvastatin calcium) 20mg significantly cut the risk of venous thromboembolism (VTE) by 43% (p =0.007) compared to placebo among men and women with low to normal cholesterol levels a...

Cymbalta(R) Significantly Reduced Osteoarthritis Knee Pain in New Study

INDIANAPOLIS, Jan. 30 /PRNewswire-FirstCall/ -- In a new study, Cymbalta (duloxetine HCl) 60-120 mg, taken once daily, reduced pain severity significantly, compared with placebo, in patients with osteoarthritis pain of the knee. Data from the 13-week randomized, double-blind, placebo-controlle...

Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome

- Results Presented at ASH Annual Meeting- SAN FRANCISCO, Dec. 6 /PRNewswire-FirstCall/ -- Sanofi-aventis today announced results of a randomized phase III study presented at the 50th Annual Meeting of the American Society of Hematology. The study in adult patients with hematological mali...

GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP

PHILADELPHIA, Dec. 6 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK ) announced positive safety and efficacy results from RAISE (RAndomized placebo- controlled ITP Study with Eltrombopag), a Phase III study of PROMACTA(R) (eltrombopag) in adults with chronic immune (idiopathic) thrombocyto...

Dronedarone (Multaq(R)) Reduced the Incidence and Duration of Hospitalization in Patients with Atrial Fibrillation

New post-hoc analysis from ATHENA Study showed that Multaq(R) on top of standard therapy significantly decreased the total number of hospital days by 28% in patients with atrial fibrillation or flutter NEW ORLEANS, Nov. 11 /PRNewswire-FirstCall/ -- New data from the landmark ATHENA trial sho...

Study Results Show Epratuzumab Provided Clinically Meaningful Reduced Disease Activity in Patients With Lupus

Encouraging Clinical Data Presented at American College of Rheumatology (ACR) meeting Show Reduced Need for Concomitant Corticosteroid Therapy SAN FRANCISCO, Oct. 27 /PRNewswire-FirstCall/ -- UCB (Euronext Brussels: UCB) announced data from two randomized controlled trials showing that treat...

ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments

- Results of two Phase III studies affirmed the clinical benefits of ACTEMRA - NUTLEY, N.J., Oct. 25 /PRNewswire/ -- Data from two Phase III studies showed that patients who suffer from the debilitating and painful effects of rheumatoid arthritis (RA) achieved significant improvements in sig...

Spherics, Inc. Announces Reduced Cognitive Impairment of Novel Extended Release Topiramate (SRx-502) as Compared to Topamax(R)

Findings Presented At The American Society Of Clinical Psychopharmacology Meeting WELLESLEY HILLS, Mass., Sept. 15 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn"), Assignee of the assets of Spherics, Inc. ("Spherics") for the benefit of creditors, announced t...

New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients

-Data Published in 'The Lancet' and Presented at ESC Congress- PHILADELPHIA, Sept. 4 /PRNewswire/ -- Results from a new international study, the GISSI Heart Failure (GISSI-HF) study, showed that 1 g/d dose of omega-3 acid ethyl esters reduced all cause mortality and hospital admissions fo...

Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation

This analysis showed that Multaq(R) (dronedarone) decreased the risk of stroke by 34% in patient with atrial fibrillation or atrial flutter already adequately treated by antithrombotic therapy BRIDGEWATER, N.J., Sept. 3 /PRNewswire-FirstCall/ -- The results of a post-hoc analysis ...

Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel

MUNICH, Germany, Sept. 3 /PRNewswire-FirstCall/ -- A sub-analysis of the TRITON-TIMI 38 clinical trial showed that treatment with prasugrel compared with clopidogrel significantly reduced the risk of new or recurrent heart attacks (7.4 percent vs. 9.7 percent, p<0.0001), regardless of whether ...

Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation

PARIS, September 3 /PRNewswire-FirstCall/ -- - This Analysis Showed That Multaq(R) (Dronedarone) Decreased the Risk of Stroke by 34% in Patients With Atrial Fibrillation or Atrial Flutter Already Adequately Treated by Antithrombotic Therapy The results of a post-hoc analysis of the data fr...

Catheter Ablation System for Atrial Fibrillation Shows Reduced Procedure Time, Remarkable Safety Profile and Excellent Outcomes in Two Clinical Studies

Important Studies Presented at the European Society of Cardiology Continue to Bring Attention to Innovative Technology CARLSBAD, Calif., Sept. 2 /PRNewswire/ -- Ablation Frontiers, Inc., announced today that two important studies, involving its innovative atrial fibrillation ablati...

Prasugrel Head-to-Head Study Showed Reduced Cardiovascular Events in Diabetes Patients by 30 Percent Compared with Clopidogrel

Sub-group analysis of landmark trial showed prasugrel substantially reduced risk of heart attack and stent thrombosis compared with clopidogrel among ACS patients with diabetes MUNICH, Germany, Aug. 31 /PRNewswire-FirstCall/ -- Patients who were diabetic and diagnosed with...

Bad News to Bad Bugs: Northern Antibiotics Develops Novel Polymyxins With Reduced Toxicity

HELSINKI, July 1 /PRNewswire/ -- The emergence of multidrug-resistant Gram-negative bacteria has necessitated the use of polymyxins as the agents of last resort despite their known nephrotoxicity. Now Northern Antibiotics Ltd, a Finnish biotech company, has developed novel polymyxin derivative...

Patients Taking Cymbalta(R) Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study

Patients on Treatment Also Experienced Improved Physical Functioning INDIANAPOLIS, June 13 /PRNewswire-FirstCall/ -- New data suggest that patients with osteoarthritis pain of the knee treated with 60 mg and 120 mg Cymbalta (duloxetine HCl) once daily experienced significant pain reduction. ...

Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes

Phase 3 data highlight sustained efficacy and benefits of early treatment with liraglutide versus glimepiride SAN FRANCISCO, June 9 /PRNewswire-FirstCall/ -- Data presented today at the 68th Scientific Sessions of the American Diabetes Association (ADA) demonstrated that once-d...

CellCept(R) and a Reduced Level of CNI Shows Trend Towards Preservation of Kidney Function Versus a Standard-Dose CNI

TORONTO, June 4 /PRNewswire/ -- The 12-month results from a multicenter trial monitoring CellCept(R) (mycophenolate mofetil) in combination with calcineurin inhibitors (CNIs) in renal transplantation was presented today at the American Transplant Congress (ATC). The study results showed that a...

Data Show Rufinamide, an Investigational Adjunctive Treatment for Lennox- Gastaut Syndrome, Reduced Drop Attacks by More Than 40%

Placebo-Controlled Study Results Published in May 20 Issue of Neurology WOODCLIFF LAKE, N.J., May 20 /PRNewswire/ -- Eisai Corporation of North America announced today the publication of a placebo-controlled study in Neurology that found patients with Lennox-Gastaut syndrome (LGS) treated with...

Pivotal Study Shows Physician/Nurse Teams Using SEDASYS(TM) System Reduced Risk of Over Sedation With Propofol

SAN DIEGO, May 19 /PRNewswire/ -- DDW 2008 Annual Meeting -- Ethicon Endo-Surgery announced today that the results from its pivotal trial demonstrated physician/nurse teams using the SEDASYS(TM) System reduced the risk of over sedation with propofol in patients undergoing screening and diagnos...

Data Presented at AAN Show That Lacosamide Significantly Reduced Pain and was Generally Well Tolerated in Patients With Diabetic Neuropathic Pain

UCB announces clinical data presented at the 60th Annual Meeting of the American Academy of Neurology (AAN) in Chicago SMYRNA, Ga., April 16 /PRNewswire/ -- UCB presented efficacy and safety results from pooled analyses of Phase II and III double-blind, randomized, placebo-controll...

Medivation's Dimebon(TM) Significantly Improved Daily Function in Alzheimer's Disease Patients, Resulting in Reduced Need for Caregiver Assistance

- Activities of Daily Living Data from Pivotal Trial Presented at American Academy of Neurology 60th Annual Meeting - SAN FRANCISCO and CHICAGO, April 15 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN ) today announced that Alzheimer's patients taking the investigationa...

Lotrel, a Single-Pill Combination for Treating High Blood Pressure, Reduced Cardiovascular Events by 20% in High-Risk Patients

- ACCOMPLISH first study to compare two single-pill combinations of commonly used high blood pressure medicines in reduction of cardiovascular events - RAS inhibition with an ACEI was the foundation of the combination therapies in this study and exceptional b...

Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases

- EPOC Results Published in March 22 Issue of The Lancet - BRIDGEWATER, N.J., March 20 /PRNewswire-FirstCall/ -- Sanofi-aventis today announced that efficacy results of the randomized phase III EORTC 40983 Intergroup study published in the March 22 issue of The Lancet showed that in eli...

Medivation's Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimer's Disease Patients, Resulting in Reduced Caregiver Distress

-- Neuropsychiatric Data from Pivotal Trial Presented at Annual Meeting of American Association for Geriatric Psychiatry -- SAN FRANCISCO and ORLANDO, Fla., March 15 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN ) today announced that clinical results from its first pivot...

Breast Cancer Treatment Is Reduced to One Week

Chicago-Area Community Hospital to Offer New Clinical Study to Breast Cancer Patients EVERGREEN PARK, Ill., Jan. 29 /PRNewswire/ -- Little Company of Mary Hospital and Health Care Centers in Evergreen Park, Illinois, near Chicago ( http://www.PursuingPainFreeCancer....

Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH)

-Patients treated with Lovenox(R) (enoxaparin sodium injection) were also less likely to be readmitted to hospital within 90 days- BRIDGEWATER, N.J., Dec 10 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today the results of a study that demonstrated total hospital direct medical cos...

LAP-BAND(R) System Weight-Loss Surgery Associated With More Than 70 Percent Reduced Risk of Death in People With Severe Obesity

Observational study published in the Annals of Surgery MELBOURNE, Australia, Nov. 21 /PRNewswire/ -- Severely obese people who received the LAP-BAND(R) Adjustable Gastric Banding System to lose weight had a 72 percent reduction in their risk of dying compared to obese people who were ...

New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings

Patients with Painful and Progressive Form of Inflammatory Spinal Arthritis Receiving Monthly Golimumab Treatment Showed Marked Improvements in Physical Function BOSTON, Nov. 7 /PRNewswire/ -- More than half of patients receiving monthly subcutaneous (SC) injections of...

Tezampanel, TorreyPines Therapeutics' Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego

Data Suggest Potential for Treating Motor System Disorders LA JOLLA, Calif., Oct. 17 /PRNewswire/-- Tezampanel, a novel small molecule currently in clinical development by TorreyPines Therapeutics, Inc. (Nasdaq: TPTX ) for the treatment of acute migraine headache, was shown in an indep...

New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy

Investigational Extended-Release Formulation Reduced Seizures in Patients Who Were Inadequately Controlled RESEARCH TRIANGLE PARK, N.C., Oct. 15 /PRNewswire-FirstCall/ -- New recently published data show that Lamictal(R)XR(TM) (lamotrigine) Extended- Release Tablets significa...

INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients

ORLANDO, Fla., Oct. 13 /PRNewswire/ -- Acutely ill, hospitalized patients with schizophrenia showed significant improvement in symptoms after taking INVEGA(TM) (paliperidone) Extended-Release Tablets as compared to SEROQUEL(R)(a) (quetiapine) and placebo. Symptom improvement was observed with ...

ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes

Results presented at the 43rd European Association for the Study of Diabetes Annual Meeting AMSTERDAM, The Netherlands, Sept. 19 /PRNewswire/ -- Results presented today at the 43rd Annual Meeting of the European Association for the Study of Diabetes demonstrate the abi...

Risedronate Reduced Risk of Fracture Among Osteoporotic Postmenopausal Women with History of Hip Fracture

HONOLULU, Sept. 17 /PRNewswire-FirstCall/ -- In a new analysis reported at the American Society for Bone and Mineral Research (ASBMR) 29th Annual Meeting, risedronate 5 mg decreased clinical fracture risk by 50% over three years relative to placebo in a group of postmenopausal women with osteo...

MedImmune's Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study

GAITHERSBURG, Md., Aug. 23 /PRNewswire/ -- MedImmune, Inc. today announced that in a Phase 3 study, motavizumab was shown to reduce hospitalizations due to respiratory syncytial virus (RSV) by 83 percent as compared to placebo (8.3 percent in placebo arm vs. 1.4 percent in motavizumab; p<0.001...

New Data Suggest Cymbalta(R) Reduced Pain in Fibromyalgia Patients With and Without Depression

INDIANAPOLIS, Aug. 21 /PRNewswire-FirstCall/ -- New data suggest that patients with fibromyalgia treated with 60mg or 120mg of Cymbalta(R) (duloxetine HCl) experienced greater reduction in pain severity beginning one week after starting duloxetine than those taking placebo (sugar pill), as mea...

In New Study, Duloxetine Reduced Non-specific Pain and Emotional Symptoms Associated with Depression

MADRID, Spain, 19 march 2007 - The antidepressant duloxetine, at a once-daily dose of 60 mg, significantly reduced non-specific pain and emotional symptoms associated with depression in a new, eight-week, placebo-controlled study of 327 adult patients with at least moderate pain and major depressi...

Lyrica Significantly Reduced Pain and Helped Patients Manage the Symptoms of Fibromyalgia, Data Show

BOSTON--(BUSINESS WIRE)--May 1, 2007 - Significantly more patients treated with Pfizer's Lyrica reduced their pain by 50 percent or more compared with placebo, according to study results presented today at the American Academy of Neurology annual meeting. Clinically, this outcome would equate to a ...